Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial involved 872 people who all started on a medicine called ustekinumab for the first 16 weeks. After that, those whose skin had not cleared enough were randomly split into two groups for a further blinded phase (meaning neither the participants nor the doctors knew who was getting which treatment): 135 people received guselkumab, and 133 received ustekinumab. A further 585 people whose skin had responded well enough continued on ustekinumab in a separate, non-randomised group. The trial was measuring how well each medicine controlled psoriasis — a skin condition causing red, scaly patches — using two scoring systems: the IGA (a doctor's overall rating of skin from 0 = clear to 4 = severe) and the PASI (a detailed score from 0 to 72, where higher means worse). The reported data shows the following numbers for the randomised groups. For the primary measure — how many check-up visits (out of a possible three, between weeks 28 and 40) each participant achieved a good IGA response (rated 0 or 1, with at least a 2-grade improvement from week 16) — the guselkumab group averaged 1.5 visits and the ustekinumab group averaged 0.7 visits. For the secondary measures over the same period: the average number of visits where participants achieved a PASI 90 response (at least 90% improvement in skin severity score) was 2.2 for guselkumab and 1.1 for ustekinumab; the average number of visits where participants' skin was rated completely clear (IGA score of 0) was 0.9 for guselkumab and 0.4 for ustekinumab. At the week 28 check-in specifically, the reported data shows that 31.1% of participants in the guselkumab group and 14.3% in the ustekinumab group achieved an IGA score of 0 or 1 with at least a 2-grade improvement. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 37906417) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Psoriasis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with plaque-type psoriasis (with or without psoriatic arthritis) for at least 6 months before starting the study.
- Your psoriasis has been rated as moderately to severely active based on a standard medical scoring system called PASI (score of 12 or higher) at both your screening and baseline appointments (confirm with trial site).
- A doctor has rated your psoriasis as at least a 3 out of 5 on a standard severity scale at both your screening and baseline appointments (confirm with trial site).
- At least 10% of your body surface area is affected by psoriasis at both your screening and baseline appointments.
- You are a suitable candidate for light therapy or systemic (whole-body) medication for psoriasis, whether or not you have tried these treatments before.
Who may not be able to join:
- You have a history of, or currently have, serious, worsening, or poorly controlled problems with your kidneys, liver, heart, blood vessels, lungs, digestive system, hormones, nervous system, blood, joints, mental health, or metabolism.
- You have unstable heart disease, such as a recent worsening of chest pain or an irregular heartbeat, or you were hospitalised for a heart problem within the last 3 months.
- You currently have cancer, or have had cancer in the last 5 years — with limited exceptions for certain treated skin cancers or cervical pre-cancers with no signs of return for at least 3 months (confirm with trial site).
- You have previously been treated with the medications guselkumab or ustekinumab.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
4 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Number of Visits at Which Participants Achieved an Investigator's Global Assessment (IGA) Response of Cleared (0) or Minimal (1) and at Least a 2 Grade Improvement (From Week 16) From Week 28 Through Week 40
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.